Literature DB >> 16598873

Inflammatory response predicts survival in renal cancer.

Cathel Kerr.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16598873     DOI： 10.1016/s1470-2045(06)70632-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial.

Authors:  B Walter; I Schrettenbrunner; M Vogelhuber; J Grassinger; K Bross; J Wilke; T Suedhoff; A Berand; W F Wieland; S Rogenhofer; R Andreesen; A Reichle
Journal:  Med Oncol       Date:  2011-05-24       Impact factor: 3.064

2.  C-reactive Protein in Patients with Metastatic Clear Cell Renal Carcinoma: An Important Biomarker for Tumor-associated Inflammation.

Authors:  Albrecht Reichle; Jochen Grassinger; Klaus Bross; Jochen Wilke; Thomas Suedhoff; Bernhard Walter; Wolf-Ferdinand Wieland; Anna Berand; Reinhard Andreesen
Journal:  Biomark Insights       Date:  2007-02-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.